Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Alvotech is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

A new cohort study published in Journal of American Medical Association suggests that biologics targeting IL-12, IL-23, and ...

Degenerative disc disease is common among young adults with PsA, with key risk factors including older age, male sex, diabetes, and inflammatory back pain.

Based on clinical trial data, abatacept was not associated with increased malignancy risks in RA or PsA; observational data indicated a higher risk vs other b/tsDMARDs.

Johnson & Johnson (JNJ) reports a Phase 3 success for its anti-inflammatory drug Tremfya in treating psoriatic arthritis.

Secukinumab treatment reduces bone erosion volume and enhances partial healing of erosions in patients with psoriatic ...

Learn about enteropathic arthritis, a common extra-intestinal symptom of Crohn’s disease that affects the joints.

The following is a summary of “Advancement and independent validation of a deep learning-based tool for automated scoring of ...

Scientists are urging quicker diagnosis and treatment of psoriatic arthritis to prevent long-term harm to patients. Psoriatic ...

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.

A new study finds that biologic therapies significantly reduce the risk of heart attacks and strokes in patients with psoriasis or psoriatic arthritis. Learn more about the cardiovascular benefits of ...